FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147704110> ?p ?o ?g. }

• W3147704110 endingPage "708" @default.
• W3147704110 startingPage "708" @default.
• W3147704110 abstract "Although limited effective and affordable treatment options exist for hidradenitis suppurativa, recent studies describe the effectiveness of a medical therapy, infliximab, for the treatment of hidradenitis suppurativa. Cost-saving biosimilar alternatives have recently become available, but no data currently exist on their safety and effectiveness.To evaluate the effectiveness of infliximab-abda vs infliximab administration associated with the treatment of hidradenitis suppurativa.This retrospective cohort study identified patients treated with infliximab or infliximab-abda between 2016 and 2020 at the dermatology clinic at the University of North Carolina at Chapel Hill. The study population included patients who met the clinical criteria for hidradenitis suppurativa and had received a continuous dose of infliximab or infliximab-abda for at least 10 weeks. In total, 62 potential participants were identified using clinical tracking lists on the electronic medical records, and 34 participants were included in the final analysis.Patients who started receiving infliximab or infliximab-abda were clinically tracked for a minimum of 10 weeks using the electronic medical record system, beginning at the time of drug initiation. Patients received loading doses of 10 mg/kg at weeks 0, 2, and 6, and then treatment was continued with a maintenance dose administered every 4 to 8 weeks.The primary outcome measure was Hidradenitis Suppurativa Clinical Response, defined as at least 50% decrease in inflammatory nodule count without any increase in number of abscesses or draining sinuses.Of 34 participants, 20 comprised the infliximab treatment group (mean [SD] age, 42.2 [13.2] years; 17 women [85%]), and 14 comprised the infliximab-abda treatment group (mean [SD] age, 35.5 [10.9] years; 13 women [93%]). The proportions of patients achieving a Hidradenitis Suppurativa Clinical Response were 71% (10 patients) in the infliximab-abda and 60% (12 patients) in the infliximab treatment group, which were not significantly different (P = .47).This cohort study found that both infliximab administration and infliximab-abda administration were associated with similar and significant improvement in disease as measured by the Hidradenitis Suppurativa Clinical Response. Infliximab-abda is likely a reasonable treatment option for hidradenitis suppurativa, and further research is warranted." @default.
• W3147704110 created "2021-04-13" @default.
• W3147704110 creator A5003013870 @default.
• W3147704110 creator A5005732654 @default.
• W3147704110 creator A5079530982 @default.
• W3147704110 date "2021-06-01" @default.
• W3147704110 modified "2023-10-17" @default.
• W3147704110 title "Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa" @default.
• W3147704110 cites W1913507263 @default.
• W3147704110 cites W2041193055 @default.
• W3147704110 cites W2132353895 @default.
• W3147704110 cites W2521512376 @default.
• W3147704110 cites W2592876716 @default.
• W3147704110 cites W2736727076 @default.
• W3147704110 cites W2768740770 @default.
• W3147704110 cites W2921799936 @default.
• W3147704110 cites W2922238701 @default.
• W3147704110 cites W2944844687 @default.
• W3147704110 cites W2953907977 @default.
• W3147704110 cites W2977938117 @default.
• W3147704110 cites W4233239893 @default.
• W3147704110 cites W4246930005 @default.
• W3147704110 doi "https://doi.org/10.1001/jamadermatol.2021.0220" @default.
• W3147704110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8027935" @default.
• W3147704110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33825849" @default.
• W3147704110 hasPublicationYear "2021" @default.
• W3147704110 type Work @default.
• W3147704110 sameAs 3147704110 @default.
• W3147704110 citedByCount "5" @default.
• W3147704110 countsByYear W31477041102021 @default.
• W3147704110 countsByYear W31477041102022 @default.
• W3147704110 crossrefType "journal-article" @default.
• W3147704110 hasAuthorship W3147704110A5003013870 @default.
• W3147704110 hasAuthorship W3147704110A5005732654 @default.
• W3147704110 hasAuthorship W3147704110A5079530982 @default.
• W3147704110 hasBestOaLocation W31477041102 @default.
• W3147704110 hasConcept C126322002 @default.
• W3147704110 hasConcept C141071460 @default.
• W3147704110 hasConcept C16005928 @default.
• W3147704110 hasConcept C167135981 @default.
• W3147704110 hasConcept C17991360 @default.
• W3147704110 hasConcept C2776002364 @default.
• W3147704110 hasConcept C2777138892 @default.
• W3147704110 hasConcept C2777575956 @default.
• W3147704110 hasConcept C2779134260 @default.
• W3147704110 hasConcept C2780132546 @default.
• W3147704110 hasConcept C2908647359 @default.
• W3147704110 hasConcept C71924100 @default.
• W3147704110 hasConcept C99454951 @default.
• W3147704110 hasConceptScore W3147704110C126322002 @default.
• W3147704110 hasConceptScore W3147704110C141071460 @default.
• W3147704110 hasConceptScore W3147704110C16005928 @default.
• W3147704110 hasConceptScore W3147704110C167135981 @default.
• W3147704110 hasConceptScore W3147704110C17991360 @default.
• W3147704110 hasConceptScore W3147704110C2776002364 @default.
• W3147704110 hasConceptScore W3147704110C2777138892 @default.
• W3147704110 hasConceptScore W3147704110C2777575956 @default.
• W3147704110 hasConceptScore W3147704110C2779134260 @default.
• W3147704110 hasConceptScore W3147704110C2780132546 @default.
• W3147704110 hasConceptScore W3147704110C2908647359 @default.
• W3147704110 hasConceptScore W3147704110C71924100 @default.
• W3147704110 hasConceptScore W3147704110C99454951 @default.
• W3147704110 hasIssue "6" @default.
• W3147704110 hasLocation W31477041101 @default.
• W3147704110 hasLocation W31477041102 @default.
• W3147704110 hasLocation W31477041103 @default.
• W3147704110 hasOpenAccess W3147704110 @default.
• W3147704110 hasPrimaryLocation W31477041101 @default.
• W3147704110 hasRelatedWork W2033249972 @default.
• W3147704110 hasRelatedWork W2047978035 @default.
• W3147704110 hasRelatedWork W2067775822 @default.
• W3147704110 hasRelatedWork W2148764617 @default.
• W3147704110 hasRelatedWork W2163737309 @default.
• W3147704110 hasRelatedWork W2169450843 @default.
• W3147704110 hasRelatedWork W2170060483 @default.
• W3147704110 hasRelatedWork W2803151199 @default.
• W3147704110 hasRelatedWork W4255489673 @default.
• W3147704110 hasRelatedWork W4256094026 @default.
• W3147704110 hasVolume "157" @default.
• W3147704110 isParatext "false" @default.
• W3147704110 isRetracted "false" @default.
• W3147704110 magId "3147704110" @default.
• W3147704110 workType "article" @default.